article Open AccessTop 1% cited

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

Journal of Clinical Oncology · 2015 · Vol. 33(26) · pp. 2863–2869

Antonio Palumbo✉Hervé Avet‐Loiseau(Institut Claudius Regaud)Stefania OlivaHenk M. Lokhorst(Vrije Universiteit Amsterdam)Hartmut GoldschmidtLaura Rosiñol(Universitat de Barcelona)Paul RichardsonS CaltagironeJuan José LahuertaThierry FaçonSara BringhenFrancesca GayMichel Attal(Institut Claudius Regaud)Roberto PasseraAndrew Spencer(Alfred Health)Massimo OffidaniShaji Kumar(Mayo Clinic)Pellegrino MustoSagar LonialMaria Teresa PetrucciRobert Z. Orlowski(Lymphoma Research Foundation)Elena ZamagniGareth J. MorganMeletios Α. DimopoulosBrian G.M. DurieKenneth C. AndersonPieter SonneveldJesús F. San MiguelMichèle CavoS. Vincent Rajkumar(Mayo Clinic)Philippe Moreau(Centre Hospitalier Universitaire de Nantes)

View via DOI Full-text PDF

Abstract

The R-ISS is a simple and powerful prognostic staging system, and we recommend its use in future clinical studies to stratify patients with NDMM effectively with respect to the relative risk to their survival.

Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors Peptidase Inhibition and AnalysisMultiple myelomaMedicineLactate dehydrogenaseInternal medicineBeta-2 microglobulinGastroenterologyStage (stratigraphy)HomogeneousNuclear medicineSurgery

MeSH terms

AdolescentAdultAgedAged, 80 and overChromosome AberrationsFemaleHumansL-Lactate DehydrogenaseMaleMiddle AgedMultiple MyelomaNeoplasm StagingIn Situ Hybridization, Fluorescence

Citations

2,132

FWCI

77.52

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Circular RNA circMTO1 acts as the sponge of microRNA‐9 to suppress hepatocellular carcinoma progression